Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

January 12, 2018: By Jon Swedien
Bausch + Lomb's Stellaris Elite

Bausch + Lomb’s Stellaris Elite

Bausch + Lomb has received CE marking for the Stellaris Elite dual-function cataract/vitrectomy system, which includes the Vitesse hypersonic vitrector, the company announced Jan. 8.

The Stellaris Elite offers adaptive fluidics, designed to provide precise aspiration control with predictive infusion management to create a responsive and controlled surgical environment for efficient lens removal, the company said.

The Vitesse vitrector uses a novel, single-needle design and continuously open port system. Vitesse is available exclusively on the Stellaris Elite.

The Stellaris Elite platform is now available in the 28 European Union countries and Iceland, Liechtenstein, Norway, and Switzerland, according to Bausch + Lomb, a New Jersey-based subsidiary of Canada’s Valeant. The platform gained US approval in April 2017.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023